Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Uterine Fibroids, Gynaecology (512)
Announcements and latest updates

test announcement

Uterine Fibroids, Gynaecology (512)

Please report any inaccuracies or issues with this guideline using our online form

Uterine fibroids (leiomyomas) are common benign tumours found in 25% of women of reproductive age. They may be associated with heavy menstrual bleeding (HMB), pelvic pressure symptoms, subfertility and pregnancy problems.

The malignant potential of fibroids is extremely low (<1%) with leiomyosarcomas typically occuring in women above the age of 60years.

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 14/11/2023

Next review date: 31/10/2027

Author(s): Aradhana Khaund.

Version: 4

Co-Author(s): Claire Higgins.

Approved By: Gynaecology Clinical Governance Group

Document Id: 512

References

Fibroids: diagnosis and management. Lumsden MA, Hamoodi I, Gupta J, Hickey M, BMJ 2015;351:h4887

A review of evidence-based management of uterine fibroids K Younas, E Hadoura, F Majoko, A Bunkheila. The Obstetrician & Gynaecologist, 2016;18:33–42

NICE Clinical Knowledge Summaries, Management of Fibroids, May 2022

Liberty 1 & 2 Al-Hendy A et al. N Engl J Med 2021;38:630-642;

Liberty 3 Study Al-Hendy A, et al. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 Dec 1;140(6):920-930.

Scottish Medicines Consortium (SMC) advice on new medicines.  SMC2442, relugolix 40mg, estradiol 1mg, norethisterone acetate 0.5mg film-coated tablets (Ryeqo®) May 2022.